文献速递泌尿生殖腹部MR

膀胱影像报告和数据系统在多模式治疗肌层浸润性膀胱癌中的新用途

Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer.
PubMed 文献 · Eur Radiol · 2023-04-13

本研究回顾78例接受多模式治疗(经尿道切除联合放化疗后部分或根治性膀胱切除)的肌层浸润性膀胱癌患者,由两名放射科医生按5分VI-RADS评分对治疗前MRI索引病灶分类。VI-RADS评分与病理完全缓解率呈负相关(p=0.00049),评分≤2或≤3预测完全缓解具有高特异度和高阳性预测值。VI-RADS评分可作为预测多模式治疗疗效的影像标志物。

要点

  • 治疗前MRI的VI-RADS评分越低,多模式治疗后病理完全缓解可能性越高。
  • VI-RADS≤2预测完全缓解特异度0.89、阳性预测值0.86,≤3特异度0.82、阳性预测值0.86。
  • 低VI-RADS评分患者可能是保留膀胱多模式治疗的良好候选者。

核心结论

  • VI-RADS评分可能作为肌层浸润性膀胱癌患者预测多模式治疗疗效的影像标志物。
  • VI-RADS评分与多模式治疗病理完全缓解发生率呈负相关(p=0.00049)。

研究设计与样本

  • 回顾性研究,纳入78例病理证实的肌层浸润性膀胱癌患者,均接受多模式治疗(经尿道切除联合放化疗后部分或根治性膀胱切除)。
  • 两名放射科医生按5分VI-RADS评分对治疗前MRI索引病灶进行分类,以膀胱切除标本组织学评估作为治疗反应参考标准。

关键影像表现/征象

  • VI-RADS评分1分者完全缓解2/2(100%),2分者16/19(84%),3分者12/14(86%),4分者7/11(64%),5分者14/32(44%)。

诊断标准与关键数值

  • 以VI-RADS≤2为切点预测多模式治疗病理完全缓解:特异度0.89(95%CI 0.71-0.98),阳性预测值0.86(95%CI 0.64-0.97)。
  • 以VI-RADS≤3为切点预测多模式治疗病理完全缓解:特异度0.82(95%CI 0.62-0.94),阳性预测值0.86(95%CI 0.70-0.95)。

临床应用与阅片要点

  • 治疗前MRI可按VI-RADS评分对肌层浸润性膀胱癌索引病灶进行结构化评分,低评分提示多模式治疗后完全缓解可能性较高。
  • VI-RADS评分可用于优化保留膀胱多模式治疗的患者选择,评分越低越可能获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To examine the clinical significance of the Vesical Imaging-Reporting and Data System (VI-RADS) in predicting outcome of multimodal treatment (MMT) in muscle-invasive bladder cancer (MIBC) patients.

METHODS: We reviewed 78 pathologically proven MIBC patients who underwent MMT including transurethral resection and chemoradiotherapy, followed by partial or radical cystectomy. Treatment response was assessed through histologic evaluation of cystectomy specimens. Two radiologists categorized the index lesions of pretherapeutic MRI according to the 5-point VI-RADS score. The associations of VI-RADS score with the therapeutic effect of MMT were analyzed. The diagnostic performance of VI-RADS scores with a cut-off VI-RADS scores ≤ 2 or ≤ 3 for predicting pathologic complete response to MMT (MMT-CR) was evaluated.

RESULTS: MMT-CR was achieved in 2 (100%) of VI-RADS score 1 (n = 2), 16 (84%) of score 2 (n = 19), 12 (86%) of score 3 (n = 14), 7 (64%) of score 4 (n = 11), and 14 (44%) of score 5 (n = 32). VI-RADS score was inversely associated with the incidence of MMT-CR (p = 0.00049). The cut-off VI-RADS score ≤ 2 and ≤ 3 could predict the favorable therapeutic outcome of MMT with high specificity (0.89 with 95% confidence interval [CI]: 0.71-0.98 and 0.82 with 95% CI: 0.62-0.94, respectively) and high positive predictive value (0.86 with 95% CI: 0.64-0.97 and 0.86 with 95% CI: 0.70-0.95, respectively).

CONCLUSION: VI-RADS score may serve as an imaging marker in MIBC patients for predicting the therapeutic outcome of MMT.

CLINICAL RELEVANCE STATEMENT: Muscle-invasive bladder cancer patients with a lower Vesical Imaging-Reporting and Data System score can be a good candidate for bladder-sparing treatment incorporating multimodal treatment.

KEY POINTS: • Vesical Imaging-Reporting and Data System (VI-RADS) score was potentially valuable for classifying pathologic tumor response in patients with muscle-invasive bladder cancer. • The likelihood of achieving complete response of multimodal treatment (MMT) decreased with increasing VI-RADS score. • VI-RADS score could serve as an imaging marker that optimizes patient selection for MMT.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Kimura, Yoshida, Tsuchiya, et al. Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer. Eur Radiol. 2023. PMID: 37045982. doi:10.1007/s00330-023-09627-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。